Control of intraocular pressure fluctuation: Are combination drugs more effective?

Expert Review of Ophthalmology

Volumn 6, Issue 2, 2011, Pages 151-154

  Feldman, Robert M ^a   Bell, Nicholas P ^a   Nagi, Kundandeep S ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

brimonidine; diurnal IOP; fixed combination therapy; IOP fluctuation; long term IOP fluctuation; short term IOP fluctuation; timolol

Indexed keywords

BRIMONIDINE; BRIMONIDINE PLUS TIMOLOL; TIMOLOL;

ARTICLE; CIRCADIAN RHYTHM; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE FLUCTUATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MONOTHERAPY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; TREATMENT DURATION;

EID: 79955075977     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/eop.11.12     Document Type: Article

References (28)

1. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am. J. Ophthalmol. 126, 487-497 (1998).
2. The Advanced Glaucoma Intervention Study (AGIS) 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am. J. Ophthalmol. 130, 429-440 (2000).
3. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression, results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 120, 1268-1279 (2002). (Pubitemid 36105431)
4. Kass MA, Heuer DK, Higginbotham EJ et al. The Ocular Hypertension Treatment Study, a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120, 701-713 (2002). (Pubitemid 34620348)
5. Lichter PR, Musch DC, Gillespie BW et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 108, 1943-1953 (2001). (Pubitemid 33032760)
6. Nouri-Mahdavi K, Hoffman D, Coleman AL et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 111, 1627-1635 (2004). (Pubitemid 39179673)
7. Bengtsson B, Leske MC, Hyman L, Heijl A. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology 114, 205-209 (2007). (Pubitemid 46161799)
8. Caprioli J. Intraocular pressure fluctuation, an independent risk factor for glaucoma? Arch. Ophthalmol. 125, 1124-1125 (2007). (Pubitemid 47258048)
9. Hong S, Seong GJ, Hong YJ. Long-term intraocular pressure fluctuation and progressive visual field deterioration in patients with glaucoma and low intraocular pressures after a triple procedure. Arch. Ophthalmol. 125, 1010-1013 (2007). (Pubitemid 47258028)
10. Nakagami T, Yamazaki Y, Hayamizu F. Prognostic factors for progression of visual field damage in patients with normal-tension glaucoma. Jpn J. Ophthalmol. 50, 38-43 (2006). (Pubitemid 43201032)
11. Sherwood MB, Craven ER, Chou C et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension, a 12-month randomized trial. Arch. Ophthalmol. 124, 1230-1238 (2006). (Pubitemid 44379855)
12. Spaeth GL, Bernstein P, Caprioli J, Schiffman RM. Control of intraocular pressure and fluctuation with fixed-combination brimonidine-timolol versus brimonidine or timolol monotherapy. Am. J. Ophthalmol. 151(1), 93-99.e4 (2011).
13. Sommer A, Tielsch JM, Katz J et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch. Ophthalmol. 109, 1090-1095 (1991).
14. Boyle JE, Ghosh K, Gieser DK, Adamsons IA. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology 105, 1945-1951 (1998). (Pubitemid 28509738)
15. Bell NP, Ramos JL, Feldman RM. Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension. Clin. Ophthalmol. 4, 1331-1346 (2010).
16. Hong S, Kim CY, Seong GJ. Long-term intraocular pressure fluctuation and visual field progression in glaucoma patients with low intraocular pressure after post-trabeculectomy phacoemulsification. J. Ocul. Pharmacol. Ther. 23, 571-576 (2007).
17. Day DG, Schacknow PN, Wand M et al. Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. 135, 138-143 (2003). (Pubitemid 36151788)
18. Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily, 1-year results in glaucoma patients. Brimonidine Study Group. Am. J. Ophthalmol. 127, 20-26 (1999). (Pubitemid 29036611)
19. Stewart WC, Stewart JA, Day D, Sharpe ED. Efficacy and safety of timolol maleate/ latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Acta Ophthalmol. Scand. 81, 242-246 (2003). (Pubitemid 36806261)
20. Stewart WC, Stewart JA, Day DG, Sharpe ED, Jenkins JN. Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy. Eye (Lond.) 18, 990-995 (2004). (Pubitemid 39430035)
21. Konstas AG, Stewart WC, Topouzis F, Tersis I, Holmes KT, Stangos NT. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. Am. J. Ophthalmol. 131, 729-733 (2001). (Pubitemid 32522641)
22. Liu JH, Medeiros FA, Slight JR, Weinreb RN. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy. Ophthalmology 116, 449-454 (2009).
23. Liu JH, Medeiros FA, Slight JR, Weinreb RN. Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure. Ophthalmology 117, 2075-2079 (2010).
24. Liu JH, Zhang X, Kripke DF, Weinreb RN. Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. Invest. Ophthalmol. Vis. Sci. 44, 1586-1590 (2003). (Pubitemid 36378585)
25. Mosaed S, Liu JH, Weinreb RN. Correlation between office and peak nocturnal intraocular pressures in healthy subjects and glaucoma patients. Am. J. Ophthalmol. 139(2), 320-324 (2005). (Pubitemid 40288278)
26. Stewart WC, Konstas AG, Nelson LA, Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology 115(7), 1117-1122.e1 (2005).
27. Wax MB, Camras CB, Fiscella RG, Girkin C, Singh K, Weinreb RN. Emerging perspectives in glaucoma, optimizing 24-hour control of intraocular pressure. Am. J. Ophthalmol. 133, S1-S10 (2002). (Pubitemid 34553482)
28. Barkana Y, Anis S, Liebmann J, Tello C, Ritch R. Clinical utility of intraocular pressure monitoring outside of normal office hours in patients with glaucoma. Arch. Ophthalmol. 124, 793-797 (2006). (Pubitemid 43877672)